The acronym nonalcoholic fatty-liver disease (NAFLD) groups a heterogeneous patient population. Although in many patients the primary driver is metabolic dysfunction, a complex and dynamic interaction of different factors (i.e., sex, presence of one or more genetic variants, coexistence of different comorbidities, diverse microbiota composition, and various degrees of alcohol consumption among others) takes place to determine disease subphenotypes with distinct natural history and prognosis and, eventually, different response to therapy. This review aims to address this topic through the analysis of existing data on the differential contribution of known factors to the pathogenesis and clinical expression of NAFLD, thus determining the different clinical subphenotypes observed in practice. To improve our understanding of NAFLD heterogeneity and the dominant drivers of disease in patient subgroups would predictably impact on the development of more precision-targeted therapies for NAFLD.

Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity / M. Arrese, J.P. Arab, F. Barrera, B. Kaufmann, L. Valenti, A.E. Feldstein. - In: SEMINARS IN LIVER DISEASE. - ISSN 0272-8087. - (2021), pp. 1-14. [Epub ahead of print] [10.1055/s-0041-1730927]

Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity

L. Valenti
Penultimo
;
2021

Abstract

The acronym nonalcoholic fatty-liver disease (NAFLD) groups a heterogeneous patient population. Although in many patients the primary driver is metabolic dysfunction, a complex and dynamic interaction of different factors (i.e., sex, presence of one or more genetic variants, coexistence of different comorbidities, diverse microbiota composition, and various degrees of alcohol consumption among others) takes place to determine disease subphenotypes with distinct natural history and prognosis and, eventually, different response to therapy. This review aims to address this topic through the analysis of existing data on the differential contribution of known factors to the pathogenesis and clinical expression of NAFLD, thus determining the different clinical subphenotypes observed in practice. To improve our understanding of NAFLD heterogeneity and the dominant drivers of disease in patient subgroups would predictably impact on the development of more precision-targeted therapies for NAFLD.
cirrhosis; fibrosis; heterogeneity; metabolic syndrome; NAFLD; NASH; nonalcoholic; nonalcoholic fatty-liver disease; steatohepatitis; steatosis
Settore MED/09 - Medicina Interna
7-lug-2021
https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0041-1730927
Article (author)
File in questo prodotto:
File Dimensione Formato  
s-0041-1730927.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 405.71 kB
Formato Adobe PDF
405.71 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/861438
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 12
social impact